AstraZeneca's GLP-1 Pill Heads To Late-Stage Trials

AstraZeneca is advancing its oral GLP-1 receptor agonist elecoglipron into Phase 3 trials after demonstrating significant results in Phase 2b studies. The VISTA trial showed 10.5% weight reduction at 26 weeks, while the SOLSTICE trial achieved 1.9% HbA1c reduction in Type 2 diabetes patients. The drug showed a favorable safety profile with mild gastrointestinal side effects.